To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Bupropion HCl 100 mg Tablets (Invamed Inc.); Drug: Wellbutrin 100 mg Tablets (Glaxo Wellcome)

• Registration Number: NCT00883155
• Lead Sponsor: Sandoz

Brief Summary

To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets under Fasting Conditions.

Detailed Description

Not available

Study Timeline

• Study Start: 1998-10
• Primary Completion: 1998-10
• Study Completion: 1998-10
• Status Verified: 2009-04
• Study First Submitted: 2009-04-16
• Study First Submitted QC: 2009-04-16
• Study First Posted: 2009-04-17
• Last Update Submitted: 2017-03-27
• Last Update Posted: 2017-03-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 36

Inclusion Criteria

• No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria

• Positive test results for HIV or hepatitis B or C.
• Treatment for drug or alcohol dependence.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
1	Bupropion HCl 100 mg Tablets (Invamed Inc.)	Bupropion HCl 100 mg Tablets (Invamed Inc.)
2	Wellbutrin 100 mg Tablets (Glaxo Wellcome)	Wellbutrin 100 mg Tablets (Glaxo Wellcome)

Primary Outcome Measures

Name	Time	Method
Bioequivalence based on AUC and Cmax	29 days